Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
AstraZeneca speeds R&D decision making with cutting-edge life sciences technology
24 Apr, 2012, 09:00 ET
PHILADELPHIA, April 24, 2012 /PRNewswire/ -- The Intellectual Property & Science division of Thomson Reuters today announced its commitment to support R&D pharmaceutical leaders with a new oncology application for mobile tablet devices, already in use by AstraZeneca executives. The rich visualization dashboard leverages content from Thomson Reuters Cortellis, the company's flagship life sciences platform, and provides real-time data for clinical oncology drug research and development activities.
"Oncology is critical for pharma, as is evidenced by the World Health Organization's projection that an estimated 13.1 million people will die from cancer in 2030, up from the 7.6 million who died in 2008," said Wendy Hamilton, senior vice president at Thomson Reuters. "The ability of drug companies to quickly find the most relevant research data and clinical information for their oncology studies, in meetings, on the move or at the bench, will allow them to make faster business decisions and focus on areas where there is unmet need."
The solution provides a series of oncology-based clinical dashboards that provide competitive information that quickly answers common questions in drug development. It is platform independent and accessible via the Internet. Mobile tablet-based devices are the primary method used for accessing the solution.
Users see at-a-glance, side-by-side comparisons of adverse events for drugs already on the market or in clinical trials. They get a deeper understanding of the drugs and how they are being targeted for diseases by segment. The comparisons visualize the level of current research and development activity around an indication, whether by company or mechanism of action, together with information on ongoing clinical trials.
The new applications represent the initial output in an ongoing partnership between Thomson Reuters and AstraZeneca, with other applications due to be released this year. The Thomson Reuters Life Sciences Professional Services team is working on similar innovative projects for other customers too.
Launched in late 2011, Cortellis is the most powerful tool of its kind for biopharmaceutical competitive intelligence, drug pipeline, and drug research and development. For more information on the oncology decision support dashboards and Cortellis, go to http://cortellis.thomsonreuters.com/.
About Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs approximately 60,000 people and operates in over 100 countries. For more information, go to www.thomsonreuters.com.
SOURCE Thomson Reuters
Share this article